title: Platelet inhibition and bleeding complications in cardiac surgery: A review.
abstract: Dual antiplatelet therapy (DAPT) with acetylsalicylic acid and a P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) reduces thrombotic events in patients with acute coronary syndrome (ACS), but it is also associated with an increased risk of bleeding complications. Excessive bleeding in cardiac surgery patients is associated with increased morbidity and mortality and high costs. In this review, different aspects of platelet inhibition in cardiac surgery patients will be discussed, including direct effects on bleeding and transfusion requirements, discontinuation and reinstitution of antiplatelet drugs before and after surgery, and the use of perioperative platelet function testing.
authors: a Department of Cardiothoracic Surgery , Sahlgrenska University Hospital , Gothenburg , Sweden.|b Department of Molecular and Clinical Medicine , Institute of Medicine, Sahlgrenska Academy at the University of Gothenburg , Gothenburg , Sweden.
authors: Emma C
authors: EC
authors: Hansson
authors: a Department of Cardiothoracic Surgery , Sahlgrenska University Hospital , Gothenburg , Sweden.|b Department of Molecular and Clinical Medicine , Institute of Medicine, Sahlgrenska Academy at the University of Gothenburg , Gothenburg , Sweden.
authors: Anders
authors: A
authors: Jeppsson
mesh_terms: D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects*; D016063:Blood Loss, Surgical / Q000401:mortality; D001803:Blood Transfusion; D006348:Cardiac Surgical Procedures / Q000009:adverse effects* / Q000401:mortality; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006801:Humans; D019990:Perioperative Care; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D010979:Platelet Function Tests; D019106:Postoperative Hemorrhage / Q000097:blood / Q000139:chemically induced* / Q000401:mortality / Q000517:prevention & control; D011237:Predictive Value of Tests; D058921:Purinergic P2Y Receptor Antagonists / Q000008:administration & dosage / Q000009:adverse effects*; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists; D001241:Aspirin
keywords: Platelets; bleeding; cardiac surgery; platelet inhibition